|Description||(±)-Clopidogrel hydrochloride is the hydrochloride salt of clopidogrel, which is a high affinity, selective and irreversible antagonist of the platelet purinergic P2Y12 receptor with IC50 value of 100 nM. It is used as a potent antithrombotic agent and requires bioactivation. It inhibits ADP-induced platelet aggregation ex vivo and functions as a prodrug. It enables its anti-aggregating activity via biotransformation to its active metabolite via CYP2C19 in the liver.|
|Purity||≥99% by HPLC|
|Synonyms||Plavix; α-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5(4H)-acetic acid, methyl ester, monohydrochloride; Methyl 2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)-2-(2-chlorophenyl)acetate hydrochloride|
Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in...
Cangrelor, an adenylic acid derivative, has been found to be a P2Y12 inhibitor that could be effective in some coronary artery diseases. It is under Phase I tri...
Clopidogrel is converted to its active metabolite by cytochrome P450 (CYP) enzymes.
MRS 2500 tetraammonium salt
MRS 2500 tetraammonium salt is a highly potent and selective antagonist of the platelet P2Y1 receptor (Ki = 0.78 nM). It inhibits ADP-induced aggregation of hum...
MRS 2211 is a competitive P2Y13 receptor antagonist (pIC50 = 5.97), with > 20-fold selectivity over P2Y1 and P2Y12 receptors. It is known that MRS 2211 inhibits...
Regrelor is a P2Y12 antagonist. In Dec 2008, Phase-II for Thrombosis in USA was discontinued.
UTPγS trisodium salt
UTPγS trisodium salt is a selective P2Y2 and P2Y4 receptor agonist.
PSB 1114, a β,γ‐difluoromethylene derivative of 4‐thio‐UTP, is a potent, selective P2Y2 agonist (EC50 = 0.134 μM),with >60-fold selectivity versus P2Y4 and P2Y6...